Overview
Impact of the COVID-19 Pandemic on Fatigue
Challenges and coping strategies
AI Healthcare Consultant for COVID Vaccine Concerns
Researchers are developing an artificial intelligence agent to understand and address the concerns about the COVID-19 vaccine among people with MS. Participants will be talking with the AI consultant for 10 – 20 minutes in an online meeting. Participants will be compensated for the participation time. Please fill out a brief screening form at the link below. A researcher will contact you to set up the meeting. Please contact [email protected] for more information about the study.
COVID-19 Vaccines
Sponsor: iConquerMSTime to Complete: 15-20 minutesCOVER-MS is a study that assesses the experiences of those diagnosed with MS who received the COVID-19 vaccines. If you have received the COVID-19 vaccine and are diagnosed with MS, visit the iConquerMS website to share your experience.
Personal Experiences
Sponsor: iConquerMS™Time to Complete: 15-20 minutesiConquerMS is conducting this survey to learn more about how people affected by MS are dealing with the COVID-19 pandemic and what has been their personal experience with COVID-19.Learn More
Submit Research Questions
Sponsor: iConquerMS™Time to Complete: 1-2 minutesiConquerMS is currently looking for research questions on the topic of COVID-19 and MS. What do you wish was better understood on this topic? Do you belong to a racial or ethnic minority group? They would especially like to hear from you. Communities of color have been affected more strongly by COVID-19 and often by MS as well.Learn More
Risk and Impact
Sponsor: University of PittsburghTime to Complete: A series of brief online questionnaires over the course of one year.A consortium of researchers are conducting a prospective survey study to examine the risk of COVID-19 and the broader impact of the pandemic in people with MS and related disorders as well as community controls. The questionnaires ask about risk factors, precaution measures, change in neurological care, COVID-19 status, neurological and psychosocial outcomes as well as social connectivity. The goal is to use the survey response from the patients and controls to better guide the patient community. For questions about the study, please contact the Principal Investigator Dr. Zongqi Xia and the research team at [email protected] or 412-360-8203.Learn More